{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:27:44Z","timestamp":1789846064163,"version":"4.0.1"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>A subunit vaccine using a defined antigen(s) may be one effective solution for controlling leishmaniasis. Because of genetic diversity in target populations, including both dogs and humans, a multiple-antigen vaccine will likely be essential. However, the cost of a vaccine to be used in developing countries must be considered. We describe herein a multiantigen vaccine candidate comprised of antigens known to be protective in animal models, including dogs, and to be recognized by humans immune to visceral leishmaniasis. The polyprotein (KSAC) formulated with monophosphoryl lipid A, a widely used adjuvant in human vaccines, was found to be immunogenic and capable of inducing protection against<jats:named-content content-type=\"genus-species\">Leishmania infantum<\/jats:named-content>, responsible for human and canine visceral leishmaniasis, and against<jats:named-content content-type=\"genus-species\">L. major<\/jats:named-content>, responsible for cutaneous leishmaniasis. The results demonstrate the feasibility of producing a practical, cost-effective leishmaniasis vaccine capable of protecting both humans and dogs against multiple<jats:named-content content-type=\"genus-species\">Leishmania<\/jats:named-content>species.<\/jats:p>","DOI":"10.1128\/cvi.05024-11","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T05:54:00Z","timestamp":1307080440000},"page":"1118-1124","source":"Crossref","is-referenced-by-count":76,"title":["KSAC, the First Defined Polyprotein Vaccine Candidate for Visceral Leishmaniasis"],"prefix":"10.1128","volume":"18","author":[{"given":"Yasuyuki","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanitha S.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raodoh","family":"Mohamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro F.","family":"Picone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia E. Z.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Vedvick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2011,6,1]]},"reference":[{"key":"key20180919073521_B1","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1086\/515265","article-title":"Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J","volume":"177","author":"Armijos","year":"1998","journal-title":"Infect. Dis."},{"key":"key20180919073521_B2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1086\/507708","article-title":"Immunotherapy for drug-refractory mucosal leishmaniasis. J","volume":"194","author":"Badaro","year":"2006","journal-title":"Infect. Dis."},{"key":"key20180919073521_B3","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","article-title":"Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis","volume":"174","author":"Basu","year":"2005","journal-title":"J. Immunol."},{"key":"key20180919073521_B4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jmb.2004.05.028","article-title":"Improved prediction of signal peptides: SignalP 3.0","volume":"340","author":"Bendtsen","year":"2004","journal-title":"J. Mol. Biol."},{"key":"key20180919073521_B5","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1016\/j.vaccine.2009.09.066","article-title":"Optimized subunit vaccine protects against experimental leishmaniasis","volume":"27","author":"Bertholet","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073521_B6","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.vaccine.2008.12.053","article-title":"KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major","volume":"27","author":"Bhaumik","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073521_B7","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/IAI.69.6.4103-4108.2001","article-title":"Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease","volume":"69","author":"Campos-Neto","year":"2001","journal-title":"Infect. Immun."},{"key":"key20180919073521_B8","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1172\/JCI112209","article-title":"Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin","volume":"76","author":"Carvalho","year":"1985","journal-title":"Invest."},{"key":"key20180919073521_B9","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD(4+) T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect. Immun."},{"key":"key20180919073521_B10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pt.2005.03.006","article-title":"Second-generation vaccines against leishmaniasis","volume":"21","author":"Coler","year":"2005","journal-title":"Trends Parasitol."},{"key":"key20180919073521_B11","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","article-title":"Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis","volume":"70","author":"Coler","year":"2002","journal-title":"Infect. Immun."},{"key":"key20180919073521_B12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat. Med."},{"key":"key20180919073521_B13","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1016\/j.vaccine.2008.05.095","article-title":"Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein","volume":"26","author":"Fernandes","year":"2008","journal-title":"Vaccine"},{"key":"key20180919073521_B14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections","volume":"20","author":"Ghosh","year":"2001","journal-title":"Vaccine"},{"key":"key20180919073521_B15","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1016\/j.vaccine.2009.02.079","article-title":"Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection","volume":"27","author":"Goto","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073521_B16","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1016\/j.vaccine.2007.08.001","article-title":"Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant","volume":"25","author":"Goto","year":"2007","journal-title":"Vaccine"},{"key":"key20180919073521_B17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.vetpar.2008.10.097","article-title":"Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs","volume":"160","author":"Goto","year":"2009","journal-title":"Vet. Parasitol."},{"key":"key20180919073521_B18","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2005.07.001","article-title":"Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals","volume":"23","author":"Gradoni","year":"2005","journal-title":"Vaccine"},{"key":"key20180919073521_B19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/IAI.42.2.702-707.1983","article-title":"Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis","volume":"42","author":"Haldar","year":"1983","journal-title":"Infect. Immun."},{"key":"key20180919073521_B20","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.4049\/jimmunol.164.9.4819","article-title":"In BALB\/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease","volume":"164","author":"Himmelrich","year":"2000","journal-title":"J. Immunol."},{"key":"key20180919073521_B21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(00)03128-7","article-title":"Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan","volume":"356","author":"Khalil","year":"2000","journal-title":"Lancet"},{"key":"key20180919073521_B22","doi-asserted-by":"crossref","first-page":"808","DOI":"10.4269\/ajtmh.2010.09-0341","article-title":"Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine","volume":"82","author":"Kumar","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"key20180919073521_B23","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.4049\/jimmunol.157.10.4537","article-title":"The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: a tissue-dependent pattern controlled by the Lsh and MHC loci","volume":"157","author":"Leclercq","year":"1996","journal-title":"J. Immunol."},{"key":"key20180919073521_B24","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.4049\/jimmunol.145.12.4306","article-title":"Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide","volume":"145","author":"Liew","year":"1990","journal-title":"J. Immunol."},{"key":"key20180919073521_B25","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2010.08.092","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis","volume":"28","author":"Llanos-Cuentas","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073521_B26","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.vaccine.2008.01.026","article-title":"Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis","volume":"26","author":"Miret","year":"2008","journal-title":"Vaccine"},{"key":"key20180919073521_B27","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1016\/j.vaccine.2007.05.010","article-title":"Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis","volume":"25","author":"Moreno","year":"2007","journal-title":"Vaccine"},{"key":"key20180919073521_B28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.7725103","article-title":"Expression cloning of a protective Leishmania antigen","volume":"268","author":"Mougneau","year":"1995","journal-title":"Science"},{"key":"key20180919073521_B29","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1128\/IAI.68.11.6289-6293.2000","article-title":"Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment","volume":"68","author":"Murray","year":"2000","journal-title":"Infect. Immun."},{"key":"key20180919073521_B30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4049\/jimmunol.151.2.929","article-title":"Role and effect of IL-2 in experimental visceral leishmaniasis","volume":"151","author":"Murray","year":"1993","journal-title":"J. Immunol."},{"key":"key20180919073521_B31","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1016\/j.vaccine.2010.07.063","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis","volume":"28","author":"Nascimento","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073521_B32","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1016\/j.vaccine.2008.09.085","article-title":"First generation leishmaniasis vaccines: a review of field efficacy trials","volume":"26","author":"Noazin","year":"2008","journal-title":"Vaccine"},{"key":"key20180919073521_B33","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.vaccine.2008.01.023","article-title":"Vaccines for leishmaniasis in the fore coming 25 years","volume":"26","author":"Palatnik-de-Sousa","year":"2008","journal-title":"Vaccine"},{"key":"key20180919073521_B34","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.vaccine.2005.02.009","article-title":"Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum","volume":"23","author":"Rafati","year":"2005","journal-title":"Vaccine"},{"key":"key20180919073521_B35","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1016\/S0264-410X(01)00081-0","article-title":"A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major","volume":"19","author":"Rafati","year":"2001","journal-title":"Vaccine"},{"key":"key20180919073521_B36","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.vaccine.2005.11.011","article-title":"Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis","volume":"24","author":"Rafati","year":"2006","journal-title":"Vaccine"},{"key":"key20180919073521_B37","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.4049\/jimmunol.140.4.1274","article-title":"Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes","volume":"140","author":"Russell","year":"1988","journal-title":"J. Immunol."},{"key":"key20180919073521_B38","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1902s28","article-title":"Animal models for the analysis of immune responses to leishmaniasis","volume":"2001","author":"Sacks","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"key20180919073521_B39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1084\/jem.171.1.115","article-title":"Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism","volume":"171","author":"Sadick","year":"1990","journal-title":"J. Exp. Med."},{"key":"key20180919073521_B40","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(98)09552-X","article-title":"Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran","volume":"351","author":"Sharifi","year":"1998","journal-title":"Lancet"},{"key":"key20180919073521_B41","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1084\/jem.181.4.1527","article-title":"A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12","volume":"181","author":"Skeiky","year":"1995","journal-title":"J. Exp. Med."},{"key":"key20180919073521_B42","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.4049\/jimmunol.161.11.6171","article-title":"LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile","volume":"161","author":"Skeiky","year":"1998","journal-title":"J. Immunol."},{"key":"key20180919073521_B43","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.4049\/jimmunol.143.12.4244","article-title":"Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response","volume":"143","author":"Squires","year":"1989","journal-title":"J. Immunol."},{"key":"key20180919073521_B44","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","article-title":"Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis","volume":"165","author":"Stager","year":"2000","journal-title":"J. Immunol."},{"key":"key20180919073521_B45","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.vaccine.2010.02.089","article-title":"Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE","volume":"28","author":"Trigo","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073521_B46","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1128\/IAI.66.7.3279-3289.1998","article-title":"Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family","volume":"66","author":"Webb","year":"1998","journal-title":"Infect. Immun."},{"key":"key20180919073521_B47","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.4049\/jimmunol.157.11.5034","article-title":"Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis","volume":"157","author":"Webb","year":"1996","journal-title":"J. Immunol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.05024-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T05:17:50Z","timestamp":1686115070000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.05024-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,1]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7,5]]},"published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1128\/CVI.05024-11"],"URL":"https:\/\/doi.org\/10.1128\/cvi.05024-11","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,1]]}}}